About the consortium

LIPID Metabolites And Pathways Strategy (LIPID MAPS®) is a multi-institutional effort created in 2003 to identify and quantitate, using a systems biology approach and sophisticated mass spectrometers, all of the major — and many minor — lipid species in mammalian cells, as well as to quantitate the changes in these species in response to perturbation.

The ultimate goal of our research is to better understand lipid metabolism and the active role lipids play in diabetes, stroke, cancer, arthritis, Alzheimer's and other lipid-based diseases in order to facilitate development of more effective treatments.

Since our inception, we have made great strides toward defining the "lipidome" (an inventory of the thousands of individual lipid molecular species) in the mouse macrophage. We have also worked to make lipid analysis easier and more accessible for the broader scientific community and to advance a robust research infrastructure for the international research community. We share new lipidomics findings and methods, hold annual meetings open to all interested investigators, and are exploring joint efforts to extend the use of these powerful new methods to new applications. Resources available include:

Our lipid classification system is the first internationally accepted lipid classification, nomenclature, and structural representation system suitable for the complex bioinformatics databasing required to analyze the numerous molecular species of lipids (initially reported in 2005 and updated in 2009 in The Journal of Lipid Research).

LIPID MAPS® is funded by a grant from the Wellcome Trust. LIPID MAPS® national team of researchers is led by Valerie O'Donnell, Co-Director of the Systems Immunity Research Institute at Cardiff University, UK.

logo LIPID MAPS® is funded by a grant from the Wellcome Trust.